Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MX69 |
Synonyms | |
Therapy Description |
MX69 is an inhibitor of the interaction between MDM2 and XIAP, which results in MDM2 degradation and subsequent repression of TP53 activation thereby possibly leading to antitumor activity (PMID: 27666947). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MX69 | MX-69 | MDM2 Inhibitor 23 | MX69 is an inhibitor of the interaction between MDM2 and XIAP, which results in MDM2 degradation and subsequent repression of TP53 activation thereby possibly leading to antitumor activity (PMID: 27666947). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 over exp TP53 wild-type | neuroblastoma | sensitive | MX69 | Preclinical - Cell culture | Actionable | In a preclinical study, a neuroblastoma cell line over expressing MDM2 and wild-type for TP53 demonstrated sensitivity to treatment with MX69 in culture, resulting in decreased cell survival (PMID: 27666947). | 27666947 |
MDM2 over exp TP53 wild-type | acute lymphoblastic leukemia | sensitive | MX69 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MX69 treatment induced cell death and inhibited cell growth in a TP53 wild-type acute lymphocytic leukemia cell line over expressing MDM2, and prolonged survival in xenograft models (PMID: 27666947). | 27666947 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|